Drug General Information
Drug ID
D0G6EI
Former ID
DCL000505
Drug Name
CP-533536
Synonyms
Evatanepag; CP-533,536; 2-(3-((((4-(1,1-dimethylethyl)phenyl)methyl)(pyridin-3-ylsulfonyl)amino)methyl)phenoxy)acetic acid; 2-[3-[[pyridin-3-ylsulfonyl-[(4-tert-butylphenyl)methyl]amino]methyl]phenoxy]acetic Acid
Drug Type
Small molecular drug
Indication Osteoporosis [ICD9: 733.0, V07.4; ICD10:M80-M81, Z79.890] Phase 2 [537118], [539228]
Company
Pfizer
Structure
Download
2D MOL

3D MOL

Formula
C25H28N2O5S
InChI
InChI=1S/C25H28N2O5S/c1-25(2,3)21-11-9-19(10-12-21)16-27(33(30,31)23-8-5-13-26-15-23)17-20-6-4-7-22(14-20)32-18-24(28)29/h4-15H,16-18H2,1-3H3,(H,28,29)
InChIKey
WOHRHWDYFNWPNG-UHFFFAOYSA-N
PubChem Compound ID
PubChem Substance ID
Target and Pathway
Target(s) Prostaglandin E2receptor, EP2 subtype Target Info Agonist [537118], [549974]
KEGG Pathway cAMP signaling pathway
Neuroactive ligand-receptor interaction
Inflammatory mediator regulation of TRP channels
Renin secretion
Pathways in cancer
Reactome Prostanoid ligand receptors
G alpha (s) signalling events
WikiPathways Prostaglandin Synthesis and Regulation
GPCRs, Class A Rhodopsin-like
Ovarian Infertility Genes
Small Ligand GPCRs
GPCR ligand binding
GPCR downstream signaling
References
Ref 537118Discovery of CP-533536: an EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation. Bioorg Med Chem Lett. 2009 Apr 1;19(7):2075-8. Epub 2009 Jan 23.
Ref 539228(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1929).
Ref 537118Discovery of CP-533536: an EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation. Bioorg Med Chem Lett. 2009 Apr 1;19(7):2075-8. Epub 2009 Jan 23.
Ref 549974Pfizer. Product Development Pipeline. March 31 2009.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.